CN107727728A - A kind of iTRAQ marks the application in osteoarthritis - Google Patents
A kind of iTRAQ marks the application in osteoarthritis Download PDFInfo
- Publication number
- CN107727728A CN107727728A CN201711169091.1A CN201711169091A CN107727728A CN 107727728 A CN107727728 A CN 107727728A CN 201711169091 A CN201711169091 A CN 201711169091A CN 107727728 A CN107727728 A CN 107727728A
- Authority
- CN
- China
- Prior art keywords
- str
- itraq
- ort
- marks
- control group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/105—Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
The invention discloses a kind of iTRAQ to mark the application in osteoarthritis, 2. 1. preparation of samples extracts STR/ort model groups and control group serum, isometric mixing is distinguished by two groups, using acetone precipitation will quantitatively 3. STR/ort model groups and control group serum differential protein press difference ratio after protein precipitation>1.2 or<0.8, the peptide hop count identified is at least>2 is selected, surveys function and possible interaction that they are played in OA grid, screens candidate's OA marks.The present invention carries out the confirmation of mark by crowd's sample, assess these OA candidate markers diagnosis OA value and analyze its correlation with clinic, it is proposed their feasibilities in terms of the clinical practices such as OA prevention, early diagnosis, and its meaning in crowd's bony articulation health early warning.
Description
Technical field
The present invention relates to genetic transcription group and proteomics field, especially a kind of iTRAQ marks combine MALDI-
Applications of the TOF MS-MS in osteoarthritis STR-ort models.
Background technology
Osteoarthritis (osteoarthritis, OA) is also known as degenerative osteoarthropathy, is one of most common joint diseases,
The pain slowly developed in joint, stiff, enlargement are mainly shown as, with joint function disturbance, or even disabled [1-2] occurs.OA
Pathogenesis be joint by science of heredity, biology and Mechanics of Machinery event(Such as heredity, metabolic disorder, strain, wound)'s
Collective effect, induces cell and matrix changes in morphology, biomethanics, molecules etc., causes articular cartilage thin
Born of the same parents, the degraded of extracellular matrix and subchondral bone and synthesis are uneven.Its final result is the softening of cartilage cell, fibrosis, ulcer
And lose, after the protective effect of cartilage is lost, subchondral bone hardens, ivory, ultimately results under spur and cartilage
The formation of bone cyst.
OA can involve the multiple joints of whole body, and its illness rate increases and increased with the age, especially endangers senior health and fitness, and give
Society brings heavy burden.OA illness rate is up to more than 50% in over-65s crowd at present, and more than 75 years old in crowd,
This numerical value can reach 80% or so.The survey data in the U.S. shows that OA causes more than 50 years old male's disablement
No. 2 killer, is only second to angiocardiopathy [5].With the world and the acceleration of Chinese society aging population, OA increasingly into
For doctors and patients or even the hot topic of social concerns.
At present, the diagnosis to OA relies primarily on clinical symptoms, imaging data and arthroscopy etc., wherein, after
Both have very big value for clear and definite joint part histopathologic change situation.The change of x-ray is evaluation OA progress in iconography
Common method, but it still has certain limitation, and its specificity and sensitiveness are poor.Studied and sent out by Pathologic specimen
Existing, when X lines are acted normally, articular cartilage may also seriously be involved;Once there is the change of X lines, disease in patient
Progressive stage [6-7] is often in, the normal function in joint and the quality of life of patient have been subjected to serious, irreversible
Influence.Magnetic resonance imaging (MRI) is high to soft tissue resolution, can be imaged from arbitrary face and multi-parameter, multi-sequence im-aging,
The change situation of cartilage can be directly displayed, contributes to OA early diagnosis, but due to expensive, it is difficult to for a wide range of
Disease assessment and generaI investigation.In addition, arthroscope is the best means for evaluating damaged articular cartilage, is considered as that diagnosis joint is soft
The goldstandard of damaged bone, it can directly observe swelling and the ulceration situation of hyaline cartilage.But it is invasive due to inspection, and
The change of cartilage deep layer and subchondral bone matter can not be shown, its clinical practice is also restrained.Therefore, probe into effective, cheap
And minimally invasive detection methods come detect subclinical OA and monitor lesion progress, to early diagnosis and effectively preventing and treating OA have
Important meaning.
With the development of molecular biology and the raising of research meanses, researcher attempts sight being placed on available for clinical pre-
Survey and assess OA biology blood serum designated object aspect [8-9].OA blood serum designated object, it is the molecule thing of joint tissue matrix
Matter or segment, they are released into blood in tissue synthesis and the metabolic process decomposed, can inhaled by enzyme linked immunological
Attached method (ELISA) or radioimmunology are measured, and are suitably applied in health examination and Mass screening, and the bone of crowd is closed
It is significant to save healthy early warning.Detection at present, analysis and determination disease blood serum mark rely primarily on proteomic techniques, use
Proteomic techniques illustrate the mutual of the change of disease marker protein expression level and disease development different phase
Relation and its rule, it has also become solve the best approach [10-11] of disease early diagnosis problem.And mass-spectrometric technique is albumen
The core of omics technology, the iTRAQ of new development over the past two years(isobaric tags for relative and absolute
Quantification, iTRAQ)Mark combines MALDI-TOF MS/MS technologies, is provided for the discovery and identification of disease marker
Qualitative, quantitative information [12], are newest in disease marker screening study and most strong means.
Therefore, MALDI-TOF MS/MS scientific discoveries and identification OA marker proteins are combined using iTRAQ marks, is mesh
Preceding energy let us screens from thousands of haemocyanins to be existed in serum really, and and can indicates OA blood serum designated object
Ideal scheme.However, because mass-spectrometric technique has high sensitivity and high-resolution characteristic, its obtained data letter
Breath is often magnanimity, and in these differential proteins with respect to magnanimity, key necessary to both being formed containing OA sexually revises,
Containing only because of the unstability of disease genome and caused by with sexually revising [13].In addition, human diseases is also extremely complex,
Old OA patient more likely suffers from the disease of multiple organ system simultaneously, even if being all the patient for only suffering from OA, because of age, sex, body
Matter, heredity etc. are different, have an impact to the express spectra of haemocyanin.How by those influence OA occurrence and development it is key
Molecule is the significant challenge of current research from non-OA specificity, unstability and with being identified in sexually revising.
To solve these key issues, this project plan first iTRAQ marks combine MALDI-TOF MS/MS find and
The technology of identification disease marker albumen is applied to osteoarthritis STR/ort models.STR/ort models are that a kind of spontaneous OA is moved
Thing model [14], the Histological assessment of its articular cartilage show, the OA incidences of disease of STR/ort mouse and the order of severity with the age by
Cumulative to add, irreversible change appears in final stage, and degenerative process is very similar to human osteoarthritic, is preferably to grind
Study carefully model [15-19] inside OA onsets and progress.In addition, STR/ort mouse models are in kind, strain, sex, age, body
Weight, activity, even health status, heredity and microorganism etc. the indifference opposite sex, temperature, humidity, illumination, noise, feed etc.
Rearing conditions are also identical, are the consistent cast materials of a kind of disease conditions [20-21], suitable for OA disease marker discovery phases
Research, can help to find specific OA candidate markers.
Biomarker has to pass through discovery or identification(Discovery), checking(Verification), confirm
(Validation)Three steps, then just enter clinical examination etc. deeper into stage [22].Therefore, this project will continue to test
Demonstrate,prove the OA serum candidate markers found in STR/ort models, including its differential expression situation and OA specificity issues.We
Intend carrying out the expression checking of candidate markers in STR/ort mouse and OA patients serums, determine differential expression trend, adopt simultaneously
Collect OA patient articular's synovia, the specificity issues of analysis candidate markers and OA lesions, make OA marks in OA clinical samples
Also it is verified.Then, our quantitative detections by deep progress OA marks in patients serum's sample, itself and OA diseases are analyzed
The relation of journey, and establish OA diagnosing models, calculate OA marks diagnosis OA sensitivity, specificity, positive predictive value and
Negative predictive value, propose their feasibilities in terms of the clinical practices such as OA prevention, early diagnosis, disease course prediction.
Therefore, based on iTRAQ marks combine MALDI-TOF MS/MS technologies, spontaneous OA animal models are utilized
STR/ort mouse, find and identification OA serum differentially expressed proteins, and to be verified they are specific and poor in OA clinical samples
After different expression, then go deep into the research of OA diagnosing models, confirm prevention, early diagnosis, the course of disease of the OA marks in OA
Effect in terms of the clinical practices such as prediction.This project provides the early warning for crowd's bony articulation health new thinking.
ITRAQ mark combine MALDI-TOF MS/MS in osteoarthritis STR/ort models are the research can not or
Scarce composition part, a kind of iTRAQ marks of the present invention combine MALDI-TOF MS-MS in osteoarthritis STR-ort models
The technical scheme of application, have no identical through retrieving domestic pharmaceutical industry industry.
The content of the invention
It is an object of the invention to provide a kind of iTRAQ marks to combine MALDI-TOF MS-MS in osteoarthritis STR-ort
Application in model.
This iTRAQ marks combine applications of the MALDI-TOF MS-MS in osteoarthritis STR-ort models,
Comprise the steps of:
1. preparation of samples:STR/ort model mices and each 10 of control mice, by the raising requirement raising of cleaning grade animal half
In barrier system;Support to 20 week old(Adult), every mouse takes blood 0.9-1.5 mL through eyeball;After 4 DEG C of blood sample stands 1 h,
5000 r/min centrifuge 5 min, take supernatant, load 0.2 mL EP pipes by 50 μ L/ pipes, carry out mark, -80 DEG C of preservations are standby
With;
2. STR/ort model groups and control group serum are extracted, by two groups of isometric mixing respectively, using acetone precipitation by albumen
It is quantitative after matter precipitation, make every group containing about 100ug total proteins, carry out carrying out pancreatin enzymolysis, reductive alkylation, iTRAQ marks successively
Strictly carried out Deng, process in accordance with iTRAQ kit specifications;STR/ort model groups and control group serum after iTRAQ is marked
Enzymolysis product mixed in equal amounts, after carrying out one-dimensional SCX and two-dimentional nano-LC chromatographic isolations, into spectrometer analysis;
3. STR/ort model groups and control group serum differential protein press difference ratio>1.2 or<0.8, the peptide hop count identified is extremely
It is few>2 is selected, utilizes Gene Ontology Consortium, Kyoto Encyclopedia of Genes and
The databases such as Genomes, protein-protein interaction prediction database are carried out to entering sortilin
Analysis, function and possible interaction that they play in OA grid are predicted, screens candidate's OA marks.
Invention beneficial effect:
The present invention intends by osteoarthritis STR/ort models, and MALDI-TOF MS/MS scientific discoveries are combined using iTRAQ marks
OA serum differentially expressed proteins, analyzing them using bioinformatics technique may performance in the signal network of OA occurrence and development
Function and interaction;It is equal in osteoarthritis STR/ort models and OA patients serums, lesion knuckle synovia to filter out those
Candidate serum OA marks specific expressed and that differential expression trend is consistent;Mark is carried out really by crowd's sample again
Recognize, assess these OA candidate markers diagnosis OA value and analyze itself and clinical correlation, propose they OA prevention,
Feasibility in terms of the clinical practices such as early diagnosis, and its meaning in crowd's bony articulation health early warning.
Embodiment
Embodiment:
This iTRAQ marks combine applications of the MALDI-TOF MS-MS in osteoarthritis STR-ort models,
Comprise the steps of:
1. preparation of samples:STR/ort model mices and each 10 of control mice, by the raising requirement raising of cleaning grade animal half
In barrier system;Support to 20 week old(Adult), every mouse takes blood 0.9-1.5 mL through eyeball;After 4 DEG C of blood sample stands 1 h,
5000 r/min centrifuge 5 min, take supernatant, load 0.2 mL EP pipes by 50 μ L/ pipes, carry out mark, -80 DEG C of preservations are standby
With;
2. STR/ort model groups and control group serum are extracted, by two groups of isometric mixing respectively, using acetone precipitation by albumen
It is quantitative after matter precipitation, make every group containing about 100ug total proteins, carry out carrying out pancreatin enzymolysis, reductive alkylation, iTRAQ marks successively
Strictly carried out Deng, process in accordance with iTRAQ kit specifications;STR/ort model groups and control group serum after iTRAQ is marked
Enzymolysis product mixed in equal amounts, after carrying out one-dimensional SCX and two-dimentional nano-LC chromatographic isolations, into spectrometer analysis;
3. STR/ort model groups and control group serum differential protein press difference ratio>1.2 or<0.8, the peptide hop count identified is extremely
It is few>2 is selected, utilizes Gene Ontology Consortium, Kyoto Encyclopedia of Genes and
The databases such as Genomes, protein-protein interaction prediction database are carried out to entering sortilin
Analysis, function and possible interaction that they play in OA grid are predicted, screens candidate's OA marks.
The foregoing is only a preferred embodiment of the present invention, but protection scope of the present invention be not limited thereto,
Any one skilled in the art the invention discloses technical scope in, technique according to the invention scheme and its
Inventive concept is subject to equivalent substitution or change, should all be included within the scope of the present invention.
Claims (1)
1. a kind of iTRAQ marks the application in osteoarthritis, it is characterised in that:Comprise the steps of:
1. preparation of samples:STR/ort model mices and each 10 of control mice, by the raising requirement raising of cleaning grade animal half
In barrier system;Support to 20 week old(Adult), every mouse takes blood 0.9-1.5 mL through eyeball;After 4 DEG C of blood sample stands 1 h,
5000 r/min centrifuge 5 min, take supernatant, load 0.2 mL EP pipes by 50 μ L/ pipes, carry out mark, -80 DEG C of preservations are standby
With;
2. STR/ort model groups and control group serum are extracted, by two groups of isometric mixing respectively, using acetone precipitation by albumen
It is quantitative after matter precipitation, make every group containing about 100ug total proteins, carry out carrying out pancreatin enzymolysis, reductive alkylation, iTRAQ marks successively
Strictly carried out Deng, process in accordance with iTRAQ kit specifications;STR/ort model groups and control group serum after iTRAQ is marked
Enzymolysis product mixed in equal amounts, after carrying out one-dimensional SCX and two-dimentional nano-LC chromatographic isolations, into spectrometer analysis;
3. STR/ort model groups and control group serum differential protein press difference ratio>1.2 or<0.8, the peptide hop count identified is extremely
It is few>2 is selected, utilizes Gene Ontology Consortium, Kyoto Encyclopedia of Genes and
The databases such as Genomes, protein-protein interaction prediction database are carried out to entering sortilin
Analysis, function and possible interaction that they play in OA grid are predicted, screens candidate's OA marks.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711169091.1A CN107727728A (en) | 2017-11-22 | 2017-11-22 | A kind of iTRAQ marks the application in osteoarthritis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711169091.1A CN107727728A (en) | 2017-11-22 | 2017-11-22 | A kind of iTRAQ marks the application in osteoarthritis |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107727728A true CN107727728A (en) | 2018-02-23 |
Family
ID=61217808
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711169091.1A Pending CN107727728A (en) | 2017-11-22 | 2017-11-22 | A kind of iTRAQ marks the application in osteoarthritis |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107727728A (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104246507A (en) * | 2012-03-26 | 2014-12-24 | 雀巢产品技术援助有限公司 | Early biomarkers of age-related low-grade inflammation |
WO2015136298A1 (en) * | 2014-03-13 | 2015-09-17 | Isis Innovation Limited | Methods and system for determining the disease status of a subject |
WO2016127035A1 (en) * | 2015-02-05 | 2016-08-11 | Duke University | Methods of detecting osteoarthritis and predicting progression thereof |
US20170030925A1 (en) * | 2010-03-05 | 2017-02-02 | The Curators Of The University Of Missouri | Biomarkers of osteoarthritis |
-
2017
- 2017-11-22 CN CN201711169091.1A patent/CN107727728A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170030925A1 (en) * | 2010-03-05 | 2017-02-02 | The Curators Of The University Of Missouri | Biomarkers of osteoarthritis |
CN104246507A (en) * | 2012-03-26 | 2014-12-24 | 雀巢产品技术援助有限公司 | Early biomarkers of age-related low-grade inflammation |
WO2015136298A1 (en) * | 2014-03-13 | 2015-09-17 | Isis Innovation Limited | Methods and system for determining the disease status of a subject |
WO2016127035A1 (en) * | 2015-02-05 | 2016-08-11 | Duke University | Methods of detecting osteoarthritis and predicting progression thereof |
Non-Patent Citations (4)
Title |
---|
AITANA BRAZA-BOÏLS ET AL.: "Analysis of early biochemical markers and regulation by tin protoporphyrin IX in a model of spontaneous osteoarthritis", 《EXPERIMENTAL GERONTOLOGY》 * |
XIAOMIN SONG ET AL.: "iTRAQ Experimental Design for Plasma Biomarker Discovery", 《JOURNAL OF PROTEOME RESEARCH》 * |
梁海波 等: "膝骨性关节炎差异表达蛋白血清标记物筛选:iTRAQ技术的重要性", 《中国组织工程研究》 * |
梁海波: "同位素相对标记技术(iTRAQ)结合双向液相色谱与质谱联用技术应用于膝骨性关节炎血清差异蛋白的实验研究", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Pizzichini et al. | Measuring airway inflammation in asthma: eosinophils and eosinophilic cationic protein in induced sputum compared with peripheral blood | |
Zoltewicz et al. | Characterization of antibodies that detect human GFAP after traumatic brain injury | |
Gordon‐Lipkin et al. | Comparative quantitative clinical, neuroimaging, and functional profiles in children with acute flaccid myelitis at acute and convalescent stages of disease | |
CN103328501A (en) | Novel biomarker and uses thereof in diagnosis, treatment of autism | |
EP3786305A1 (en) | Biomarker for depression and use thereof | |
CN105705652B (en) | Method for assisting in the differential diagnosis of stroke | |
Martin et al. | Prevalence and risk factors of bronchiectasis in rheumatoid arthritis: a systematic review and meta-analysis | |
JP2012073274A (en) | Protein profile for osteoarthritis | |
Sun et al. | Identification of proteomic signatures associated with COPD frequent exacerbators | |
Siroux et al. | Trajectories of IgE sensitization to allergen molecules from childhood to adulthood and respiratory health in the EGEA cohort | |
CN107167610B (en) | autism biomarker and detection kit thereof | |
Ren et al. | Biochemical markers for the early identification of osteoarthritis: systematic review and meta-analysis | |
CN107655998A (en) | A kind of iTRAQ marks the application method in osteoarthritis | |
Beydoun et al. | Plasma neurofilament light as blood marker for poor brain white matter integrity among middle-aged urban adults | |
CN107907693A (en) | A kind of foundation of OA markers | |
CN107727729A (en) | A kind of method for building up of OA candidate markers diagnostic model | |
Zhang et al. | A novel splice site variant in the POPDC3 causes autosomal recessive limb‐girdle muscular dystrophy type 26 | |
CN107918014A (en) | A kind of osteoarthritis marker confirms | |
CN107727728A (en) | A kind of iTRAQ marks the application in osteoarthritis | |
Sandhu et al. | Association of synovial fluid and urinary C2C-HUSA levels with surgical outcomes post-total knee arthroplasty | |
CN107643406A (en) | A kind of osteoarthritis mark checking | |
Nigoro et al. | Obesity with radiological changes or depression was associated with worse knee outcome in general population: a cluster analysis in the Nagahama study | |
CN110396538A (en) | Migraine biomarker and application thereof | |
Pereira et al. | Biomarkers for intervertebral disc and associated back pain: From diagnosis to disease prognosis and personalized treatment | |
Qu et al. | Reproducible abnormalities and diagnostic generalizability of white matter in Alzheimer’s disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180223 |